Share This Page
Suppliers and packagers for generic pharmaceutical drug: CHLORPHENIRAMINE MALEATE
✉ Email this page to a colleague
CHLORPHENIRAMINE MALEATE
Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.
| Applicant | Tradename | Generic Name | Dosage | NDA | NDA/ANDA | Supplier | Package Code | Package | Marketing Start |
|---|---|---|---|---|---|---|---|---|---|
| Avanthi Inc | CHLORPHENIRAMINE MALEATE | chlorpheniramine maleate | TABLET, EXTENDED RELEASE;ORAL | 040829 | ANDA | KVK-Tech, Inc. | 10702-017-01 | 100 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (10702-017-01) | 2010-06-15 |
| Avanthi Inc | CHLORPHENIRAMINE MALEATE | chlorpheniramine maleate | TABLET, EXTENDED RELEASE;ORAL | 040829 | ANDA | KVK-Tech, Inc. | 10702-017-06 | 60 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (10702-017-06) | 2010-06-15 |
| Avanthi Inc | CHLORPHENIRAMINE MALEATE | chlorpheniramine maleate | TABLET, EXTENDED RELEASE;ORAL | 040829 | ANDA | KVK-Tech, Inc. | 10702-017-24 | 24 TABLET, FILM COATED, EXTENDED RELEASE in 1 CARTON (10702-017-24) | 2010-06-15 |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >NDA/ANDA | >Supplier | >Package Code | >Package | >Marketing Start |
Chlorpheniramine Maleate Suppliers: Market Overview and Key Manufacturers
This report analyzes the global supply landscape for chlorpheniramine maleate, a widely used antihistamine. The market is characterized by a number of established manufacturers, with production concentrated in Asia. Key market drivers include the ongoing demand for allergy and cold relief medications and the generic nature of the drug.
What is Chlorpheniramine Maleate?
Chlorpheniramine maleate is a first-generation antihistamine used to treat symptoms of the common cold and allergic reactions such as hay fever, hives, and runny nose. It functions by blocking the action of histamine, a substance in the body that causes allergic symptoms [1]. The drug is available in various formulations, including tablets, capsules, syrups, and injections. Its long history of use and established efficacy contribute to consistent market demand.
Global Production Landscape
The manufacturing of chlorpheniramine maleate is global, with a significant portion of production capacity located in Asia, particularly in China and India. These regions benefit from lower manufacturing costs and established pharmaceutical supply chains. Western markets, including North America and Europe, also have some domestic production but often rely on imports for a substantial portion of their supply.
The active pharmaceutical ingredient (API) is manufactured by specialized chemical companies and then sold to drug formulators who produce the final dosage forms. The quality and consistency of API production are paramount, with manufacturers adhering to strict regulatory standards such as Good Manufacturing Practices (GMP).
Key Production Regions and Their Strengths
- China: Dominant producer of bulk pharmaceutical chemicals, including APIs. Benefits from large-scale manufacturing infrastructure and cost competitiveness.
- India: A major global supplier of generic APIs and finished pharmaceutical products. Strong regulatory framework and expertise in complex chemical synthesis.
- Europe: Maintains high-quality manufacturing standards and is a source for specialized or high-purity grades.
- North America: Possesses domestic production capabilities, often focusing on niche markets or serving regulatory requirements for local sourcing.
Leading Chlorpheniramine Maleate Manufacturers
The market for chlorpheniramine maleate API is served by a number of established chemical and pharmaceutical companies. The following list identifies key players based on reported production capacity, market share, and industry recognition.
Table 1: Key Chlorpheniramine Maleate API Manufacturers
| Manufacturer Name | Country of Origin | Primary Focus | Notes |
|---|---|---|---|
| Shandong Xinhua Pharmaceutical Co., Ltd. | China | API Manufacturing | Large-scale producer, significant global market presence. |
| Zhejiang NHU Co., Ltd. | China | API Manufacturing | Diversified chemical producer with a strong pharmaceutical division. |
| Anhui Renrui Pharmaceutical Co., Ltd. | China | API Manufacturing | Focus on pharmaceutical intermediates and APIs. |
| Zhejiang Medicine Co., Ltd. | China | API Manufacturing | Known for a broad portfolio of APIs and vitamin products. |
| IOL Chemicals and Pharmaceuticals Limited (IOLCP) | India | API Manufacturing | Major Indian producer of APIs, including ibuprofen and chlorpheniramine. |
| Shasun Pharmaceuticals Ltd. (now part of Strides Pharma Science) | India | API Manufacturing | Historically a significant supplier of various APIs. |
| Dipharma Francis S.r.l. | Italy | API Manufacturing | European producer with a focus on high-quality APIs. |
| Cadila Healthcare (Zydus Cadila) | India | API and Formulation | Integrated pharmaceutical company with API manufacturing capabilities. |
Data sourced from company reports and industry analyses. Specific production volumes are proprietary.
Manufacturing Standards and Certifications
Manufacturers of chlorpheniramine maleate API must comply with stringent international regulatory requirements. Key certifications and standards include:
- Good Manufacturing Practices (GMP): Mandated by regulatory bodies such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and others. GMP ensures that products are consistently produced and controlled according to quality standards.
- Drug Master Files (DMFs): Submitted to regulatory agencies, providing detailed information about the manufacturing process, facilities, and quality control of an API. This allows formulators to reference the DMF in their drug product applications.
- Certificates of Suitability to the monographs of the European Pharmacopoeia (CEP): Issued by the European Directorate for the Quality of Medicines & HealthCare (EDQM), demonstrating that the quality of an API is suitably controlled by the relevant monograph of the European Pharmacopoeia.
Market Dynamics and Trends
The chlorpheniramine maleate market is mature and largely driven by generic drug demand.
Demand Drivers
- Prevalence of Allergic Conditions: The consistent incidence of allergies and respiratory ailments globally underpins steady demand for antihistamines.
- Cold and Cough Remedies: Chlorpheniramine maleate is a common ingredient in over-the-counter (OTC) and prescription cold and cough formulations.
- Cost-Effectiveness: As a well-established and off-patent drug, chlorpheniramine maleate offers a cost-effective treatment option, particularly for markets with price sensitivities.
- Emerging Markets: Increasing access to healthcare and growing disposable incomes in emerging economies contribute to broader consumption of pharmaceutical products.
Challenges and Considerations
- Competition from Newer Antihistamines: Newer generations of antihistamines (e.g., loratadine, cetirizine) offer reduced sedative effects and are often preferred for chronic use. This limits the growth potential for first-generation antihistamines like chlorpheniramine maleate, though its affordability maintains a significant market share.
- Regulatory Scrutiny: Manufacturers face continuous regulatory oversight regarding API quality, impurity profiles, and supply chain integrity.
- Price Pressures: The generic nature of the drug leads to intense price competition among API suppliers.
- Supply Chain Volatility: Geopolitical factors, raw material availability, and logistical disruptions can impact supply chains.
Quality and Regulatory Landscape
The quality of chlorpheniramine maleate API is critical for the safety and efficacy of the final drug product. Regulatory agencies worldwide set specifications for purity, impurity limits, and analytical testing.
Key Quality Parameters
- Assay: The content of chlorpheniramine maleate, typically expressed as a percentage.
- Related Substances/Impurities: Identification and quantification of known and unknown impurities, which must be within acceptable limits. Common impurities can arise from synthesis byproducts or degradation.
- Heavy Metals: Limits for heavy metal contamination.
- Loss on Drying/Water Content: Measures the amount of volatile matter present.
- Residual Solvents: Limits on residual organic solvents used during the manufacturing process.
Pharmacopoeial Standards
Manufacturers must ensure their API meets the standards set by major pharmacopoeias, including:
- United States Pharmacopeia (USP)
- European Pharmacopoeia (Ph. Eur.)
- Japanese Pharmacopoeia (JP)
- Indian Pharmacopoeia (IP)
Compliance with these standards is a prerequisite for market access in respective regions.
Supply Chain Management for Pharmaceutical Companies
For pharmaceutical companies formulating chlorpheniramine maleate products, securing a reliable and high-quality API supply is essential. This involves:
- Supplier Qualification: Rigorous vetting of potential API manufacturers, including site audits, review of quality systems, and assessment of regulatory compliance (e.g., GMP certification, DMF filings).
- Quality Agreements: Establishing formal agreements with suppliers that define quality specifications, change control procedures, and responsibilities for any deviations.
- Batch Testing: Independent testing of incoming API batches to confirm they meet all predefined specifications.
- Supply Chain Diversification: Identifying multiple qualified suppliers to mitigate risks associated with single-source dependencies.
- Long-Term Contracts: Securing supply through longer-term contracts can provide price stability and ensure consistent availability.
Key Takeaways
- The global chlorpheniramine maleate API market is dominated by manufacturers in China and India, driven by cost advantages and established production capacities.
- Established players like Shandong Xinhua Pharmaceutical Co., Ltd. and IOL Chemicals and Pharmaceuticals Limited are significant suppliers.
- Quality and regulatory compliance, including GMP certification and adherence to pharmacopoeial standards (USP, Ph. Eur.), are critical for market access and product safety.
- Demand is sustained by the widespread use of chlorpheniramine maleate in allergy and cold remedies, though competition from newer antihistamines limits significant growth.
- Pharmaceutical companies must prioritize robust supplier qualification, quality agreements, and supply chain diversification to ensure consistent access to high-quality API.
Frequently Asked Questions
What are the primary regulatory bodies overseeing chlorpheniramine maleate API production?
Key regulatory bodies include the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), Japan's Pharmaceuticals and Medical Devices Agency (PMDA), and India's Central Drugs Standard Control Organisation (CDSCO).
How do impurity profiles of chlorpheniramine maleate API vary between manufacturers?
Impurity profiles can vary based on the specific synthesis route employed by each manufacturer, the quality of raw materials used, and the effectiveness of purification steps. Manufacturers must report and control impurities within pharmacopoeial limits.
Is chlorpheniramine maleate production susceptible to raw material shortages?
Like many pharmaceutical APIs, production can be affected by shortages or price fluctuations of key chemical precursors. Global supply chain disruptions and specific chemical intermediate availability can impact manufacturing.
What is the typical shelf life of chlorpheniramine maleate API?
The typical shelf life for chlorpheniramine maleate API, when stored under recommended conditions, is generally between two to five years. Specific retest dates are provided by individual manufacturers.
Are there significant differences in quality grades of chlorpheniramine maleate API available on the market?
While all API intended for pharmaceutical use must meet pharmacopoeial standards, variations can exist in impurity profiles and the stringency of a manufacturer's internal quality control beyond pharmacopoeial requirements. This is why rigorous supplier qualification is crucial.
Citations
[1] National Center for Biotechnology Information. (2023). Chlorpheniramine Maleate. PubChem Compound Summary. Retrieved from https://pubchem.ncbi.nlm.nih.gov/compound/Chlorpheniramine-maleate
More… ↓
